Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Aurinia Pharmaceuticals Inc.

Get SEC filing alerts via email and in your feed for Aurinia Pharmaceuticals Inc.

AUPH

Aurinia Pharmaceuticals Inc.

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company specializing in therapies for autoimmune diseases with high unmet needs. Its core product, LUPKYNIS (voclosporin), is the first FDA-approved oral treatment for adult lupus nephritis, marketed in the U.S. and licensed internationally. Aurinia develops novel immunosuppressants like AUR200 targeting B cell pathways. The company operates through direct sales and partnerships, leveraging proprietary patents and contract manufacturing to serve patients and healthcare providers globally.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Aurinia Pharmaceuticals Inc.

1
1
Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals Reports 24% Revenue Growth to $77.7 Million in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals Reports 25% Revenue Growth and $287.2 Million Net Income for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals Reports 27% Increase in Net Product Sales for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals Reports 22.3% Revenue Growth and Significant Net Income Increase in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals Reports 24% Revenue Growth to $62.5 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals Reports 36% Increase in Net Product Sales for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals Reports 24.3% Revenue Growth, Net Income Turnaround in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments